Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

1.

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus.

Clements ML, Betts RF, Tierney EL, Murphy BR.

J Clin Microbiol. 1986 Jul;24(1):157-60.

3.

Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Powers DC, Sears SD, Murphy BR, Thumar B, Clements ML.

J Clin Microbiol. 1989 Dec;27(12):2666-71.

4.

Live Victoria/75-ts-1[E] influenza A virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus.

Douglas RG Jr, Markoff LJ, Murphy BR, Chanock RM, Betts RF, Hayden FG, Levine MM, Van Blerk GA, Sotman SB, Nalin DR.

Infect Immun. 1979 Oct;26(1):274-9.

5.

Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine.

Johnson PR Jr, Feldman S, Thompson JM, Mahoney JD, Wright PF.

J Med Virol. 1985 Dec;17(4):325-35.

PMID:
4078559
6.

Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination.

Nelson KM, Schram BR, McGregor MW, Sheoran AS, Olsen CW, Lunn DP.

Vaccine. 1998 Aug;16(13):1306-13.

PMID:
9682395
7.
9.

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.

Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura S, Kurata T, Sata T.

J Med Virol. 2004 Oct;74(2):328-35.

PMID:
15332283
10.

A contribution of cellular immunity to protection against influenza in man.

Jennings R, Fenton RJ, McEntegart MG, Potter CW.

Med Microbiol Immunol. 1978 Nov 17;166(1-4):51-62.

PMID:
723791
11.

Safety and efficacy of "Alice" influenza virus vaccine in normal healthy adults.

Zaky DA, Douglas RG Jr, Betts RF, Roth FK, Rinehart CJ, Hogan PW.

J Infect Dis. 1976 Jun;133(6):669-75.

PMID:
946973
12.
15.

Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine.

Potter CW, Jennings R, Phair JP, Clarke A, Stuart-Harris CH.

J Infect Dis. 1977 Mar;135(3):423-31.

PMID:
850080
17.

Temperature-sensitive mutants of influenza A virus: evaluation of the Alaska/77-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers.

Murphy BR, Chanock RM, Douglas RG, Betts RF, Waterman DH, Holley HP Jr, Hoover DL, Suwanagool S, Nalin DR, Levine MM.

Arch Virol. 1980;65(2):169-73.

PMID:
7425857
18.

Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.

Tamura S, Asanuma H, Tomita T, Komase K, Kawahara K, Danbara H, Hattori N, Watanabe K, Suzuki Y, Nagamine T, et al.

Vaccine. 1994 Sep;12(12):1083-9.

PMID:
7998417
19.
20.

Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry.

Worrall EE, Sudarisman, Priadi A.

Vaccine. 2009 Jun 24;27(31):4161-8. doi: 10.1016/j.vaccine.2009.04.058. Epub 2009 May 9.

PMID:
19406183

Supplemental Content

Support Center